MAYZENT (Novartis Pharmaceuticals Australia Pty Ltd)
Product name
MAYZENT
Date registered
Evaluation commenced
Decision date
Approval time
209 working days (255)
Active ingredients
siponimod
Registration type
NCE/NBE
Indication
MAYZENT (film-coated tablet) is indicated for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS).